{"id":67068,"date":"2026-06-02T13:24:47","date_gmt":"2026-06-02T05:24:47","guid":{"rendered":"https:\/\/flcube.com\/?p=67068"},"modified":"2026-06-02T13:24:48","modified_gmt":"2026-06-02T05:24:48","slug":"changchun-high-new-tech-secures-fda-approval-for-gensci145-mutation-selective-pi3k%ce%b1-inhibitor-for-pik3ca-mutant-solid-tumors","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67068","title":{"rendered":"Changchun High &amp; New Tech Secures FDA Approval for GenSci145, Mutation-Selective PI3K\u03b1 Inhibitor for PIK3CA-Mutant Solid Tumors"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Changchun High &amp; New Technology Industries (Group) Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/000661:SHE\">SHE: 000661<\/a>) announced it has received <strong>clinical trial approval<\/strong> from the <strong>U.S. Food and Drug Administration (FDA)<\/strong> for <strong>GenSci145<\/strong>, its investigational <strong>mutation-selective PI3K\u03b1 inhibitor<\/strong>, in patients with locally advanced or metastatic solid tumors harboring <strong>PIK3CA mutations<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone-amp-development-timeline\" class=\"wp-block-heading\">Regulatory Milestone &amp; Development Timeline<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Changchun High &amp; New Technology Industries (Group) Inc. (SHE: 000661)<\/td><\/tr><tr><td><strong>Drug Candidate<\/strong><\/td><td>GenSci145 \u2013 mutation-selective PI3K\u03b1 inhibitor<\/td><\/tr><tr><td><strong>FDA Status<\/strong><\/td><td>Clinical trial approval granted<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Locally advanced or metastatic solid tumors with PIK3CA mutations<\/td><\/tr><tr><td><strong>China Status<\/strong><\/td><td>Cleared for clinical studies in same indication (January 2026)<\/td><\/tr><tr><td><strong>Development Strategy<\/strong><\/td><td>Simultaneous global development in US and China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target:<\/strong> PIK3CA hotspot mutations \u2013 key driver in tumor initiation and progression<\/li>\n\n\n\n<li><strong>Selectivity:<\/strong> Highly selective for mutant PI3K\u03b1 over wild-type enzyme<\/li>\n\n\n\n<li><strong>Key Differentiation:<\/strong> Avoids concurrent inhibition of wild-type PI3K\u03b1, reducing traditional toxicities<\/li>\n\n\n\n<li><strong>Blood-Brain Barrier:<\/strong> Demonstrates good penetration in preclinical models<\/li>\n\n\n\n<li><strong>Safety Advantage:<\/strong> No hyperglycemia observed in preclinical studies \u2013 addresses major limitation of earlier-generation inhibitors<\/li>\n\n\n\n<li><strong>Therapeutic Rationale:<\/strong> Overcomes resistance to endocrine therapy, chemotherapy, and targeted therapies in PIK3CA-mutant cancers<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-need-amp-competitive-landscape\" class=\"wp-block-heading\">Clinical Need &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Analysis<\/th><\/tr><\/thead><tbody><tr><td><strong>PIK3CA Mutation Prevalence<\/strong><\/td><td>Present in ~40% of HR+\/HER2- breast cancers, 30% of colorectal cancers, and multiple other solid tumors<\/td><\/tr><tr><td><strong>Current PI3K\u03b1 Inhibitors<\/strong><\/td><td>Alpelisib (Piqray) approved but limited by toxicity (hyperglycemia, rash, diarrhea) due to poor selectivity<\/td><\/tr><tr><td><strong>Unmet Medical Need<\/strong><\/td><td>Better-tolerated PI3K\u03b1 inhibitors could significantly expand treatable patient population<\/td><\/tr><tr><td><strong>Market Opportunity<\/strong><\/td><td>Global PI3K inhibitor market projected to reach $3.8 billion by 2030; mutation-selective agents represent next-generation opportunity<\/td><\/tr><tr><td><strong>Competitive Differentiation<\/strong><\/td><td>GenSci145&#8217;s mutation selectivity and absence of hyperglycemia could provide significant therapeutic advantage<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-preclinical-evidence-amp-safety-profile\" class=\"wp-block-heading\">Preclinical Evidence &amp; Safety Profile<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>GenSci145<\/th><th>Earlier-Generation PI3K\u03b1 Inhibitors<\/th><\/tr><\/thead><tbody><tr><td><strong>Mutation Selectivity<\/strong><\/td><td>High selectivity for PIK3CA hotspot mutations<\/td><td>Poor selectivity, inhibits wild-type PI3K\u03b1<\/td><\/tr><tr><td><strong>Hyperglycemia<\/strong><\/td><td><strong>Not observed<\/strong> in preclinical studies<\/td><td>Common (up to 60% of patients)<\/td><\/tr><tr><td><strong>Rash\/Diarrhea<\/strong><\/td><td>Reduced incidence expected<\/td><td>Frequent dose-limiting toxicities<\/td><\/tr><tr><td><strong>CNS Penetration<\/strong><\/td><td>Good blood-brain barrier penetration<\/td><td>Limited CNS activity<\/td><\/tr><tr><td><strong>Therapeutic Window<\/strong><\/td><td>Potentially wider due to improved safety<\/td><td>Narrow due to on-target toxicities<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-implications-amp-market-outlook\" class=\"wp-block-heading\">Strategic Implications &amp; Market Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dual-Market Acceleration:<\/strong> Simultaneous US and China development de-risks regulatory pathway and accelerates global timeline<\/li>\n\n\n\n<li><strong>Breast Cancer Focus:<\/strong> Initial commercial opportunity in HR+\/HER2- breast cancer with PIK3CA mutations<\/li>\n\n\n\n<li><strong>Platform Potential:<\/strong> Success could enable expansion into other PIK3CA-mutant indications including colorectal, endometrial, and head\/neck cancers<\/li>\n\n\n\n<li><strong>Partnership Value:<\/strong> Novel mechanism and improved safety profile likely to attract global pharma interest<\/li>\n\n\n\n<li><strong>Commercial Premium:<\/strong> Superior tolerability supports premium pricing versus existing PI3K\u03b1 inhibitors<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The FDA approval positions GenSci145 as a potential best-in-class PI3K\u03b1 inhibitor that could redefine the treatment paradigm for PIK3CA-mutant solid tumors by addressing the critical toxicity limitations that have hampered earlier-generation agents.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, clinical development plans, and commercial expectations for GenSci145. Actual results may differ due to risks including clinical trial outcomes, safety findings, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/\u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8GenSci145\u7247\u5883\u5916\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u6279\u51c6\u7684\u516c\u544a-1.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8GenSci145\u7247\u5883\u5916\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u6279\u51c6\u7684\u516c\u544a (1).\"><\/object><a id=\"wp-block-file--media-a5efaac4-da3d-44a0-813e-aa6d66b11f69\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/\u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8GenSci145\u7247\u5883\u5916\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u6279\u51c6\u7684\u516c\u544a-1.pdf\">\u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8GenSci145\u7247\u5883\u5916\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u6279\u51c6\u7684\u516c\u544a (1)<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/\u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8GenSci145\u7247\u5883\u5916\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u6279\u51c6\u7684\u516c\u544a-1.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-a5efaac4-da3d-44a0-813e-aa6d66b11f69\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Changchun High &amp; New Technology Industries (Group) Inc. (SHE: 000661) announced it has received clinical&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[2929,62,1171],"class_list":["post-67068","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-changchun-high-new-technology-industries","tag-clinical-trial-approval-initiation","tag-she-000661"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Changchun High &amp; New Tech Secures FDA Approval for GenSci145, Mutation-Selective PI3K\u03b1 Inhibitor for PIK3CA-Mutant Solid Tumors - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Changchun High &amp; New Technology Industries (Group) Inc. (SHE: 000661) announced it has received clinical trial approval from the U.S. Food and Drug Administration (FDA) for GenSci145, its investigational mutation-selective PI3K\u03b1 inhibitor, in patients with locally advanced or metastatic solid tumors harboring PIK3CA mutations.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67068\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Changchun High &amp; New Tech Secures FDA Approval for GenSci145, Mutation-Selective PI3K\u03b1 Inhibitor for PIK3CA-Mutant Solid Tumors\" \/>\n<meta property=\"og:description\" content=\"Changchun High &amp; New Technology Industries (Group) Inc. (SHE: 000661) announced it has received clinical trial approval from the U.S. Food and Drug Administration (FDA) for GenSci145, its investigational mutation-selective PI3K\u03b1 inhibitor, in patients with locally advanced or metastatic solid tumors harboring PIK3CA mutations.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67068\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-02T05:24:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-02T05:24:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67068#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67068\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Changchun High &amp; New Tech Secures FDA Approval for GenSci145, Mutation-Selective PI3K\u03b1 Inhibitor for PIK3CA-Mutant Solid Tumors\",\"datePublished\":\"2026-06-02T05:24:47+00:00\",\"dateModified\":\"2026-06-02T05:24:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67068\"},\"wordCount\":513,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Changchun High &amp; New Technology Industries\",\"Clinical trial approval \\\/ initiation\",\"SHE: 000661\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67068#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67068\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67068\",\"name\":\"Changchun High &amp; New Tech Secures FDA Approval for GenSci145, Mutation-Selective PI3K\u03b1 Inhibitor for PIK3CA-Mutant Solid Tumors - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-02T05:24:47+00:00\",\"dateModified\":\"2026-06-02T05:24:48+00:00\",\"description\":\"Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced it has received clinical trial approval from the U.S. Food and Drug Administration (FDA) for GenSci145, its investigational mutation-selective PI3K\u03b1 inhibitor, in patients with locally advanced or metastatic solid tumors harboring PIK3CA mutations.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67068#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67068\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67068#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Changchun High &amp; New Tech Secures FDA Approval for GenSci145, Mutation-Selective PI3K\u03b1 Inhibitor for PIK3CA-Mutant Solid Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Changchun High &amp; New Tech Secures FDA Approval for GenSci145, Mutation-Selective PI3K\u03b1 Inhibitor for PIK3CA-Mutant Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","description":"Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced it has received clinical trial approval from the U.S. Food and Drug Administration (FDA) for GenSci145, its investigational mutation-selective PI3K\u03b1 inhibitor, in patients with locally advanced or metastatic solid tumors harboring PIK3CA mutations.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67068","og_locale":"en_US","og_type":"article","og_title":"Changchun High &amp; New Tech Secures FDA Approval for GenSci145, Mutation-Selective PI3K\u03b1 Inhibitor for PIK3CA-Mutant Solid Tumors","og_description":"Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced it has received clinical trial approval from the U.S. Food and Drug Administration (FDA) for GenSci145, its investigational mutation-selective PI3K\u03b1 inhibitor, in patients with locally advanced or metastatic solid tumors harboring PIK3CA mutations.","og_url":"https:\/\/flcube.com\/?p=67068","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-02T05:24:47+00:00","article_modified_time":"2026-06-02T05:24:48+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67068#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67068"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Changchun High &amp; New Tech Secures FDA Approval for GenSci145, Mutation-Selective PI3K\u03b1 Inhibitor for PIK3CA-Mutant Solid Tumors","datePublished":"2026-06-02T05:24:47+00:00","dateModified":"2026-06-02T05:24:48+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67068"},"wordCount":513,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Changchun High &amp; New Technology Industries","Clinical trial approval \/ initiation","SHE: 000661"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67068#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67068","url":"https:\/\/flcube.com\/?p=67068","name":"Changchun High &amp; New Tech Secures FDA Approval for GenSci145, Mutation-Selective PI3K\u03b1 Inhibitor for PIK3CA-Mutant Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-02T05:24:47+00:00","dateModified":"2026-06-02T05:24:48+00:00","description":"Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced it has received clinical trial approval from the U.S. Food and Drug Administration (FDA) for GenSci145, its investigational mutation-selective PI3K\u03b1 inhibitor, in patients with locally advanced or metastatic solid tumors harboring PIK3CA mutations.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67068#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67068"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67068#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Changchun High &amp; New Tech Secures FDA Approval for GenSci145, Mutation-Selective PI3K\u03b1 Inhibitor for PIK3CA-Mutant Solid Tumors"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67068","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67068"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67068\/revisions"}],"predecessor-version":[{"id":67070,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67068\/revisions\/67070"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67068"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67068"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67068"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}